Press Releases & Company Updates | WuXi AppTec

News Press Releases Access the latest corporate news and announcements for WuXi AppTec, including business milestones, partner collaborations, quality and regulatory updates, and financial results. Access the latest corporate news and announcements for WuXi AppTec, including business milestones, partner collaborations, quality and regulatory updates, and financial results. Filter By 2026/10/07 WuXi AppTec Earns EcoVadis Gold Medal for Third Consecutive Year, Ranking Among Global Top 5% for Sustainability SHANGHAI, October 7, 2026 – WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), has received a Gold medal from EcoVadis for the third consecutive year, reflecting the Company's consistent commitment to sustainability. Read more 2026/08/30 WuXi AppTec Continues to Reward Shareholders, Further Increasing Interim Dividend to RMB 1.51 Billion Shanghai, August 30, 2026 – WuXi AppTec Co., Ltd. (Stock Codes: 603259.SH/2359.HK), a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announces the distribution of its 2026 interim cash dividend. Building on its inaugural interim dividend of RMB 1.03 billion in 2025, the Company has further increased its 2026 interim dividend payout to RMB 1.51 billion. While accelerating the expansion of global capacity and capabilities, the Company remains committed to returning value to shareholders. Read more 2026/08/03 WuXi AppTec Delivers Strong H1 2026 Results and Raises Full-Year Guidance, Driven by Greater Success of Multiple Customers' Products and CRDMO Model WuXi AppTec, a leading global pharmaceutical CRDMO, today announced financial results for the first half ending June 30, 2026. The Company raised its full-year guidance, citing strong performance across revenue, profit, and cash flow driven by the greater success of multiple customers' products and its unique integrated CRDMO platform. Read more 2026/07/21 WuXi AppTec Named Constituent of the FTSE4Good Index Series for Fourth Consecutive Year SHANGHAI, July 21, 2026 – WuXi AppTec, a leading global pharmaceutical CRDMO (Contract Research, Development, and Manufacturing Organization), announced it has been named in the FTSE4Good Index Series for the fourth consecutive year, reflecting the Companys' sustained commitment to sustainability. Read more 2026/06/12 An Update on Our Legal Action Challenging 1260H Designation We are reaching out to make you aware of a decisive action we are taking to address the U.S. Department of Defense’s erroneous designation of our company, and to protect the interests of our customers, partners, employees and shareholders. Read more